The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of Zn-.sub.2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as adrenergin receptor agonists, adrenergin receptor antagonists, and/or glycemic control agents.

Use of fibulin-5 in the manufacture of a medicament for treating or preventing formation of a keloid scar or a medical condition associated therewith is provided herewith.

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-.sub.2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as adrenergin receptor agonists, adrenergin receptor antagonists, and/or glycemic control agents.

The present invention relates to a composition comprising a cross-linked compound (A) selected from the group polysulphated and unsulphated polysaccharides, polysulphated and unsulphated glycosaminoglycans, polysulphated and unsulphated proteoglycans, and polysulphated and unsulphated glycoproteins, and/or autologous cells reprogrammed to synthetize and secrete the compound (A), and an analogue of mammalian insulin-growth factor-1 (B) wherein amino acid residues are modified, removed or substituted that maintain or enhance insulin-like growth factor type 1 receptor avidity and affinity and wherein amino acid residues are modified, removed or added that reduce insulin-like growth factor binding protein avidity and affinity. The composition is particularly suitable for prolonging the viscosupplementation effect post-treatment of damaged articular joints.

The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-.sub.2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of increasing skeletal muscle mass, and methods of bringing about a weight reduction or reduction in obesity. Also provided are pharmaceutical compositions for use thereof.

The present invention relates to a method for controlling a glycosylation pattern of a recombinant glycoprotein, comprising culturing a cell comprising polynucleotide encoding a recombinant glycoprotein in a culture medium comprising insulin.

A protein functionalized anti-inflammatory nanoparticle and a method of preparing the protein functionalized anti-inflammatory nanoparticle is disclosed. The protein functionalized anti-inflammatory nanoparticle includes a central core comprising a hyaluronic acid coated chitosan nanoparticle and surface adsorbed anti-inflammatory proteins forming an outer shell around the central core, wherein the surface adsorbed anti-inflammatory protein is AGP (alpha-1-acid glycoprotein). The method of preparation includes dispersing chitosan nanoparticles in acetic acid/acetate buffer to produce a dispersion, adding an equal amount of acetate buffer containing hyaluronic acid under vigorous stirring to form hyaluronic coated chitosan nanoparticle (HA-CS) and functionalizing the hyaluronic coated chitosan nanoparticle with surface adsorbing anti-inflammatory protein AGP, to form the protein functionalized anti-inflammatory nanoparticle.

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-?.sub.2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as ? adrenergin receptor agonists, ? adrenergin receptor antagonists, and/or glycemic control agents.

The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

The invention relates a method for producing a stable recombinant protein, comprising growing a non-naturally occurring host cell in a culture medium to produce a recombinant protein, and making a composition comprising the recombinant protein and a polysorbate. The production of endogenous lipoprotein lipase by the host cell is reduced. The endogenous lipoprotein lipase is present in the composition in a small amount, and is capable of degrading the polysorbate. The invention also relates to the relevant host cells and compositions, and preparation thereof.